CLDI PRESS-RELEASE SEC Filing Analysis

Latest settled — T+20d

CLDI ▼ -31.11% at T+20d

SHORT call ✓ call won +31.11% · α vs SPY +30.96% · entry $0.3600 → $0.2480

Next anchor: T+60d in 10d

Last close $0.1760 (close May 22) · +51.11% from $0.3600 entry (call sign-flipped)

Entry anchored
Mar 9, 03:59 PM ET
via Databento tick

T+1d

-3.89%

call +3.89% · α +3.78%

$0.3460

settled 3mo ago

T+5d

-12.78%

call +12.78% · α +11.87%

$0.3140

settled 2mo ago

T+20d

-31.11%

call +31.11% · α +30.96%

$0.2480

settled 7w ago

T+60d

—

call — · α —

—

in 10d

Price Chart

Loading chart...

Executive Summary

Calidi Biotherapeutics (CLDI) has closed a public offering, raising approximately $6.0 million in gross proceeds by selling over 12 million shares and accompanying warrants. The offering included three series of warrants with varying expiration terms and reset provisions, indicating significant potential future dilution.

Key Financial Metrics

Deal Value

$6.0M

Actionable Insight

Traders should anticipate significant downward pressure on share price due to extreme dilution risk; warrant overhang and low current valuation suggest high speculative risk. Monitor for insider selling or further capital raises.

Key Facts

Closed underwritten public offering with full over-allotment exercise, raising $6.0 million in gross proceeds.
Sold 12,094,631 shares (or pre-funded warrants) and three series of warrants (J, K, L), each exercisable for 12,094,631 shares at $0.50 per share.
Warrants have expiration terms of 6 months (L), 1 year (K), and 5 years (J), with reset provisions on exercise price.
Market cap is only $3M while gross proceeds are $6M, suggesting substantial dilution for existing shareholders.
Company is on OTC exchange and in early development stage with lead candidate CLD-401 still in IND-enabling studies.

Financial Impact

Approximately $6.0 million in gross proceeds, but with potential for over 36 million additional shares upon warrant exercise, representing massive dilution relative to current market cap of $3M.

dilutionmarket_capshare_countequity_value

Risk Factors

Extreme share dilution from over 36 million potential new shares from warrants.
Low market cap ($3M) relative to offering size ($6M) increases volatility and downside risk.
Forward-looking statements about drug development carry high uncertainty; no clinical data or revenue yet.

Market Snapshot

Exchange

OTC

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3252397

5 reports for CLDI

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for CLDI — sortable, filterable
	Type				Now
May 22, 2026 1d ago	Press Release BEARISH ★ 7/10	—	awaiting T+20	—	—
Apr 20, 2026 4w ago	Press Release BULLISH ★ 7/10	$0.2500 $0.1830	▼ −26.80%	▼ −31.00%	$0.1760 (−29.60%)
Mar 27, 2026 8w ago	Press Release MIXED ★ 5/10	$0.2390 $0.2240	▼ −6.28%	▼ −18.87%	$0.1760 (−26.36%)
Mar 10, 2026 10w ago	Press Release BEARISH ★ 7/10	$0.3600 $0.2480	▲ +31.11%	▲ +30.96%	$0.1760 (+51.11%)
Mar 5, 2026 11w ago	Press Release NEUTRAL ★ 4/10	$0.3610 $0.2450	▼ −32.13%	▼ −30.09%	$0.1760 (−51.25%)

US Market Status

Market Closed — Opens Tue (34h 50m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access